In addition, the pateclizumab blocking the ability of LTα and LTαβ to activate TNFR1, TNFR2, and LTβR did not improve clinical outcome in an RA trial (Kennedy et al., 2014). The gene discussed is LTBR; the disease is rheumatoid arthritis.